|
IT1110460B
(it)
*
|
1977-03-02 |
1985-12-23 |
Ciba Geigy Ag |
Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
|
|
FR2639942B1
(fr)
*
|
1988-12-02 |
1991-03-29 |
Sanofi Sa |
Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
US5665756A
(en)
*
|
1994-08-03 |
1997-09-09 |
Hoechst Marion Roussel, Inc. |
Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
|
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
|
AU6776196A
(en)
*
|
1995-08-16 |
1997-03-12 |
Eli Lilly And Company |
Potentiation of serotonin response
|
|
IN182588B
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
|
IN186677B
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
|
1999-11-12 |
2001-10-20 |
Sun Pharmaceutical Ind Ltd |
|
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
|
US20080021085A1
(en)
*
|
2000-04-13 |
2008-01-24 |
Mayo Foundation For Medical Education And Research |
Method of reducing abeta42 and treating diseases
|
|
US7256191B2
(en)
*
|
2000-04-24 |
2007-08-14 |
Aryx Therapeutics |
Materials and methods for the treatment of depression
|
|
JP2003531169A
(ja)
|
2000-04-24 |
2003-10-21 |
アリックス セラピューティクス |
うつ病治療のための材料と方法
|
|
NZ532033A
(en)
*
|
2001-10-12 |
2006-11-30 |
Azevan Pharmaceuticals Inc |
2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
|
|
EP2316469A1
(en)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Delivery system and methods for protecting and administering dextroamphetamine
|
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
|
US20050042284A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Myriad Genetics, Incorporated |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
|
EP1663398B1
(en)
|
2003-09-12 |
2009-11-25 |
Pfizer Limited |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
|
|
WO2005051919A1
(en)
*
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
|
ES2515092T3
(es)
|
2003-12-11 |
2014-10-29 |
Sunovion Pharmaceuticals Inc. |
Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
CA2567249A1
(en)
*
|
2004-04-19 |
2006-10-05 |
Jds Pharmaceuticals, Llc |
Lithium combinations, and uses related thereto
|
|
MXPA06012165A
(es)
*
|
2004-04-29 |
2007-01-17 |
Keystone Retaining Wall System |
Chapas para muros, muros de contencion y similares.
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
CN104922117A
(zh)
|
2005-03-22 |
2015-09-23 |
阿泽范药品公司 |
用于治疗月经前病症的β-内酰氨基链烷酸
|
|
PE20070093A1
(es)
*
|
2005-04-22 |
2007-02-07 |
Wyeth Corp |
Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
|
|
AR056980A1
(es)
|
2005-04-22 |
2007-11-07 |
Wyeth Corp |
Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
|
|
MX2007013179A
(es)
*
|
2005-04-22 |
2008-01-16 |
Wyeth Corp |
Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
|
|
EP1871358A1
(en)
*
|
2005-04-22 |
2008-01-02 |
Wyeth |
Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
|
|
WO2007008758A2
(en)
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
JP5328349B2
(ja)
*
|
2005-07-19 |
2013-10-30 |
アゼヴァン ファーマスーティカルズ，インコーポレイテッド |
ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
|
|
EA200800360A1
(ru)
*
|
2005-07-22 |
2008-06-30 |
Мириад Дженетикс, Инк. |
Формуляции с высоким содержанием лекарства и дозированные формы
|
|
EP2377530A3
(en)
|
2005-10-21 |
2012-06-20 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
RU2008135326A
(ru)
*
|
2006-03-24 |
2010-04-27 |
Вайет (Us) |
Терапевтические композиции для лечения депрессии
|
|
JP4615470B2
(ja)
*
|
2006-03-29 |
2011-01-19 |
卓郎 簑和田 |
大脳の認知力を用いた疾患治療・予防の方法および医薬
|
|
AU2007249435A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
JP2009536669A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス，インコーポレイティド |
アンジオテンシン調節による神経新生
|
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
|
AU2007292848A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
WO2008034032A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Azevan Pharmaceuticals, Inc. |
Beta-lactam cannabinoid receptor modulators
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
|
US20080171750A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation Of Neurogenesis With Use of Modafinil
|
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
EP2491038B1
(en)
|
2009-10-23 |
2016-04-06 |
Janssen Pharmaceutica N.V. |
Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
|
|
JP5815552B2
(ja)
|
2009-12-08 |
2015-11-17 |
ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ |
眼疾患を治療する化合物および方法
|
|
ES2662350T3
(es)
|
2010-07-01 |
2018-04-06 |
Azevan Pharmaceuticals, Inc. |
Procedimientos para el tratamiento del trastorno por estrés postraumático
|
|
WO2012123922A1
(en)
|
2011-03-17 |
2012-09-20 |
Lupin Limited |
Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
|
|
KR101427221B1
(ko)
*
|
2012-08-29 |
2014-08-13 |
주식회사 에스텍파마 |
플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
|
|
EP2981518B1
(en)
|
2013-04-03 |
2021-03-03 |
ZCL Chemicals Ltd. |
"an improved process for the preparation of fluvoxamine maleate"
|
|
PL3104847T3
(pl)
|
2014-02-07 |
2021-07-05 |
Támogatott Kutatócsoportok Irodája |
Nowe zastosowanie związków agonistycznych receptora sigma-1
|
|
SG10202001065SA
(en)
|
2014-03-28 |
2020-04-29 |
Azevan Pharmaceuticals Inc |
Compositions and methods for treating neurodegenerative diseases
|
|
EP4091634A1
(en)
|
2016-03-10 |
2022-11-23 |
Janssen Pharmaceutica NV |
Methods of treating depression using orexin-2 receptor antagonists
|
|
CA3044746A1
(en)
|
2016-11-24 |
2018-05-31 |
Sigmadrugs Kutato Korlatolt Felelossegu Tarsasag |
Compositions for organ preservation
|
|
CA3075759A1
(en)
|
2017-09-15 |
2019-03-21 |
Azevan Pharmaceuticals, Inc. |
Compositions and methods for treating brain injury
|
|
AU2020316013A1
(en)
|
2019-07-19 |
2022-02-17 |
Arx, Llc |
Non-sedating dexmedetomidine treatment regimens
|
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|